CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity

9Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

While CD8+ cytotoxic T cells have long been considered the primary effector in controlling tumors, the involvement of CD4+ “helper” T cells in anti-tumor immunity has been underappreciated. The investigations of intra-tumoral T cells, fueled by the recent advances in genomic technologies, have led to a rethinking of the indirect role of CD4+ T cells that have traditionally been described as a “helper”. Accumulating evidence from preclinical and clinical studies indicates that CD4+ T cells can acquire intrinsic cytotoxic properties and directly kill various types of tumor cells in a major histocompatibility complex class II (MHC-II)-dependent manner, as opposed to the indirect “helper” function, thus underscoring a potentially critical contribution of CD4+ cytotoxic T cells to immune responses against a wide range of tumor types. Here, we discuss the biological properties of anti-tumor CD4+ T cells with cytotoxic capability and highlight the emerging observations suggesting their more significant role in anti-tumor immunity than previously appreciated.

Cite

CITATION STYLE

APA

Jeong, S., Jang, N., Kim, M., & Choi, I. K. (2023). CD4+ cytotoxic T cells: an emerging effector arm of anti-tumor immunity. BMB Reports, 56(3), 140–144. https://doi.org/10.5483/BMBRep.2023-0014

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free